# Exenatide for Myocardial Protection During Reperfusion Study

Study · id `cardio:ct-nct01938235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01938235](<https://clinicaltrials.gov/study/NCT01938235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01938235

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 198 participants.

## Technical summary

Registry record NCT01938235. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 198 participants (planned count; ClinicalTrials.gov record NCT01938235, source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT01938235, source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)
- Primary completion: 2017-07 (anticipated) (ClinicalTrials.gov record NCT01938235, source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)
- Completion: 2018-01 (anticipated) (ClinicalTrials.gov record NCT01938235, source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT01938235, source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01938235-2016-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Exenatide for Myocardial Protection During Reperfusion Study
- Acronym: EMPRES
- Condition: Myocardial Infarction
- Intervention (Drug): Exenatide
- Intervention (Drug): Placebo
- Lead sponsor: University Health Network, Toronto
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: University Health Network, Toronto (`cardio:org-university-health-network-toronto`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: d08add24689348fea07dc2348c482b64e0a17ff6dcbee79bbf88a903852a801c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
